cyrilzakka/clinical-trials huggingface dataset:
Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief

The purpose of the study is to investigate the effectiveness of a sun lotion containing a specific Jellyfish sting inhibitor versus regular sun lotions as controls. In addition, to investigate the effectiveness of hot/cold immersion for the treatment of Cyanea sp stings versus local pain relief with prescription free pharmaceutical drug (Xylocain 30 mg/ml (3%) lidocain).


Eligibility Criteria:
Inclusion Criteria:

* Volunteers
* men or women
* aged 18 or over

Exclusion Criteria:

* People with atopic diseases, e.g., asthma, allergic rhinorrhea or rhinitis, hay fever, or atopic skin inflammation
* People who suffer from skin diseases in the testing regions or whose inner forearms are too hairy to allow for interpretation of the test
* People who have used any medical or cosmetic product on either arm for 48 hours before the start of the experiment
* People who are taking antihistamines or steroids
* Subjects with medical conditions which, in the opinion of the investigator, pose risks that would prohibit participating
* Subjects with a history of keloid formation will be excluded from the Jellyfish protocol
* Subjects with allergy to lidocain or other local pain substances

If the arms contain hair that might reduce the jellyfish tentacle contact with the skin, the arm must be shaved in advance, so the skin has no sign of piling or any skin damage before the test.
Magnetic Field Modulation Pillow for Insomnia Clinical Trial

This interventional study was designed to explore the clinical effect of magnetic field modulation system on insomnia patients and provide a new solution for insomnia treatment.

Patients with insomnia receiving this sleep pillow with magnetic system or not would be observed in months.The effect of sleep pillow with magnetic system for insomnia would evaluated.

Eligibility Criteria:
Inclusion Criteria:

1.18 to 65 years old. 2.Primary Insomnia

Exclusion Criteria:

1. Secondary Insomnia
2. Pilot, high-altitude operator
3. Pregnant, lactating women
4. Patients with serious disease
5. The researchers believe that the candidates are not eligible
Study to Support Fetal Heart Rate and Uterine Contraction for Preterm Labor in Singleton and Multiple Pregnancies

The purpose of this study is to compare the Monica AN24 fetal monitor to previously FDA approved devices for Fetal Heart Rate and Uterine Contractions in labor for Multiples and pre term labor.

Clinical Investigation for a non-inferiority/equivalence study that aims to determine the acceptable performance of the Monica AN24 during the first and when possible the second stages of labor by determining whether the Monica AN24 fetal heart rate (FHR) and uterine contractions (UC) monitoring device is non-inferior/equivalent to Doppler FHR and tocodynamometer UC using direct fetal scalp electrode (FSE) FHR and intrauterine pressure catheter (IUPC) UC as a reference, either collected simultaneously with the Monica and Doppler FHR/tocodynamometer UC data, or from previous studies to define the expected accuracy and success rate when comparing Monica FHR and UC with Doppler FHR and tocodynamometer UC respectively

Eligibility Criteria:
Inclusion Criteria:

* She is \>=24weeks 0days but less than 36 completed weeks, with a singleton pregnancy or \>=34weeks 0days with a multiple pregnancy and has been admitted to the Labor and Delivery Unit
* She is in the latent phase of spontaneous labor, or has been admitted for induction of labor
* She has given her informed consent to participate as a subject
* She has none of the exclusion criteria

Exclusion Criteria:

* Known major fetal malformation or chromosome abnormality
* Involvement in another clinical trial currently or previously in this pregnancy
* Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, sensitivity to adhesives)
* Significant medical or obstetric problem that in the investigator's opinion would make the woman incapable of taking part in the study
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.

Anemia has been identified as a common complication and a widespread problem in the cancer population. Anemia is a condition in which a patient has below normal levels of hemoglobin, the substance in red blood cells that carries oxygen to all parts of the body. People with severe anemia may experience fatigue and shortness of breath with activity. Therefore, this condition can have a negative influence on a person's quality of life. Epoetin alfa, used to treat anemia in cancer patients, is a genetically engineered protein that stimulates red blood cell production. This study investigates treatment of anemia using epoetin alfa during chemotherapy in adult patients with cancer. The study is intended to collect information on normal medical practice and routine anemia management performed at the participating centers. This is an observational, non-randomized, prospective, comparative, parallel-group survey performed in The Netherlands. Patients with various severities of disease may enter the survey as soon as their epoetin alfa treatment starts and will be followed until the end of their epoetin alfa treatment. Patient data are collected in Case Report Forms (CRFs) until 4 weeks after the end of treatment with epoetin alfa. At the end of treatment completed CRFs will be collected. The assessment of effectiveness/response will be based on the following: cancer type and status, chemotherapy and other anti-cancer treatment, hemoglobin levels, use of blood transfusions, and serum iron levels and iron supplementation. Safety evaluations include the incidence of serious and non-serious adverse events. Because the study is observational, dosage, administration and duration of treatment is at discretion of treating physician.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease
* Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment
* Patients must receive epoetin alfa treatment (expected treatment duration is at least 4 weeks)

Exclusion Criteria:

* Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form and patients participating in either of our observational studies, EVALUATE or COMPARE
23-gauge Pars Plana Vitrectomy With Silicone Oil Injectionsilicone Oil Injection With Surgical

Objective: to evaluate anatomical and visual outcomes of 23-gauge vitrectomy for retinal detachment with silicone oil injection in fifty cases. The rate of recurrence, the incidence of proliferative vitreoretinopathy (PVR) and the value of risk factors.

Participants and Methods: fifty cases with RD with mixture of epiretinal and subretinal membranes were collected. Pars plan vitrectomy, 23gauge vitrectomy were done to these cases, then silicone oil removed 6 weeks after primary surgery.

Main Outcome Measures: The anatomical success rate,the failure rate ,the rate of retinal breaks in both groups, and reproliferation rate.

50 Patients were included if they had retinal detachment, moderate degrees of PVR, PVR ≥ Grade C, previous buckle surgery and pseudophakia. A good and correct assessment of the detached retina was done. Investigator followed the Lincoff rules to find the retinal breaks. Investigator performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Investigator used Perfluorocarbon liquid (PFCL) for attaching the retina with its gravity. Then performing PFCL against air exchange.The retina will be attached under air tamponade. Laser photocoagulation was performed in the air-filled eye.

Investigator applied the laser effects confluently surrounding all retinal breaks. Then silicone oil (1000 centistokes) was injected as a final step and permanent tamponade.After 3-6 months investigator removed the silicone and examined the retina for 6 weeks after surgery to detect the recurrent cases.

Eligibility Criteria:
Inclusion Criteria:

* they had retinal detachment,
* moderate degrees of PVR
* PVR ≥ Grade C
* previous buckle surgery
* pseudophakia.

Exclusion Criteria:

* the retinal tear was greater than 90 degrees
* presence of intravitreal foreign body
* previous vitrectomy done before
* if follow-up data were unavailable for a minimum follow-up of 6 months following the final retinal procedure.
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

Observational study of elderly individuals diagnosed with Non-Valvular Atrial Fibrillation and Heart Failure who are beginning oral blood thinners


Eligibility Criteria:
Inclusion Criteria:

* Were age greater than or equal to 65 years as of the index date
* Had greater than or equal to 1 diagnosis of AF prior to or on the index date
* Had greater than or equal to 1 diagnosis claim of HF during the 12 months prior to or on the index date
* Had 1 or more pharmacy claim for oral blood thinners

Exclusion Criteria:

* Claims indicating diagnosis or procedure for hip/knee replacement surgery within 6 weeks prior to index date
* Pharmacy claim for warfarin, apixaban, dabigatran, edoxaban or rivaroxaban during the 12-month baseline period
* Greater than 1 oral anticoagulants prescription claim on the index date and/or with a follow-up less than 1 day
* Had medical claim indicating VTE in the 12 months prior to index date

Other protocol defined inclusion/exclusion criteria could apply
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2101 and AD-2102 in healthy male subjects.

To evaluate the pharmacokinetic Interaction, safety and tolerability of the combination compared with the administration of AD-2101 and AD-2102.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male between 19 and 50 years of age at the time of screening
* Weight above 50 kg and body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2

Exclusion Criteria:

* Clinically significant disease or history of clinically significant disease such as cardiovascular, respiratory, liver, kidney, digestive, hematologic/oncologic, endocrine, immunologic, urinary, psychiatric
* Gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery
* A person who has a history of drug abuse
* AST, ALT, Total bilirubin values over than 2 times of UNL at screening
* Creatinine clearance under 80mL/min
Wise Mind: Environmental Approach for Obesity Prevention

The study will be conducted in four Catholic schools with children enrolled in Grades 2 through 6. Girls and boys and children of all racial types are eligible for participation in the study. We anticipate that approximately 1,000 to 1200 children will volunteer for the study. We request enrollment of 1200 children. To participate, parents must grant written consent and the child must assent by signing a consent form that is attached. Two of the four schools that volunteer for participation in the study and are approved by the research team, will be randomly assigned to a health promotion program called "Wise Mind for Diet and Physical Activity. The other two schools will be randomly assigned to a program called "Wise Mind for Avoidance of Alcohol, Drugs, and Tobacco." Students will receive the program in the school that they attend. They will not be allowed to select one of the programs and will receive only one program, i.e., the program in their school. Both health promotion programs will last for two academic years. Each year, every child that is a research participant will be tested on two occasions, once during the first two months of school (Sept and Oct), and once during the last two months of school (March and April). Testing will not be conducted during May in order to avoid interference with school activities at the end of the academic year. All children (in all four schools) will have the same testing. The testing will involve confidential measurement of eating habits, food intake, physical activity habits, attitudes about alcohol, drugs, and tobacco, body weight and height, body fatness, body image, mood, and self-esteem. The measurement techniques that will be used for this measurement will include: questionnaires, weighing, measurement of height, and photography of foods before and after eating. All measurements will be confidential and will not be released to anyone that is not involved in the management of the study, including school personnel. The total time requirement for each testing period is expected to be approximately three hours, spread over four testing periods during a two-week period. The testing periods will be conducted in conjunction with school administrators and will not be scheduled to conflict with important school activities, classes, or academic tests. A Data and Safety Monitoring Board (DSMB) will be organized to provide oversight for the conduct of the study.


Eligibility Criteria:
* Must be a student in one of the four catholic schools in Baton Rouge that have elected to participate in the study.
* Must be in the second through sixth grade at the start of the study.
The Impact of Musical Engagement on Medical Resident Well-being

It is common knowledge that music has a positive impact on human well-being. It is also well-known that medical residents are frequently stressed and burnt out. With these two thoughts in mind, the investigators want to explore how participating in a musical engagement program may positively impact medical resident well-being. The investigators hope to do this by hosting four informal musical engagement sessions with medical residents, which will involve playing instruments, improvising, and reading sheet music. To study the impact that this program has on participants, investigators will ask participants to complete a survey. The investigators hope to find that participants are positively impacted by participation in the study, in terms of factors like stress reduction and minimized burnout symptoms. Hopefully, the study results may inform residency program curriculum designers in the future may incorporate music into wellness programming.


Eligibility Criteria:
Inclusion Criteria:

1. Participants will be residents in the Family Medicine program at McMaster University, in any year of study
2. Participants may be on any rotation in their program schedule and located at any site
3. Participants may be of any gender identity, age, ethnicity, and sexual orientation
4. Must identify as a "musician", whether casual, professional, or somewhere in between - however, they require enough musical training so that they may comfortably participate in the planned sight reading and improvisation within the study
5. Participants must be able to supply their own physical instrument for sessions
6. Must be aged 18 or over
7. Must be English-speaking

Exclusion Criteria:

1. Potential participant may not be a resident of any other residency program, or be from a university other than McMaster
2. If a participant is unable to participate in two or more musical sessions, they will not be included in this study
3. If a participant is unable to complete the qualitative and quantitative survey forms in their entirety, they will not be included in this study
Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery

This trial offers support and assistance to patients wishing to quit smoking in order to increase the success rate of smoking cessation and all the benefits associated with it. Patients will be monitored by a tobacco specialist and will be able to benefit from one or more therapies complementary to Nicotine Replacement Therapy (NRT): Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy.

The study RESPIRE is aiming to identify some interventions to be proposed as part of a smoking cessation programme for smokers with cancer requiring surgical treatment and wishing to stop smoking. We aim to compare different smoking cessation methods in addition to the currently recommended treatments: Nicotine Replacement Therapy (NRT). These procedures are: Cognitive Behavioural Therapy (CBT), Motivational Interviewing (MI) or hypnotherapy in order to improve the success rate of smoking cessation in this specific population.

All patients wishing to be supported to stop smoking will be randomized and will be followed by a tobacco specialist before and after surgery. They will receive NRT for 12 months.

Smoking assessment, exhaled CO measurement, questionnaires will be completed regularly to assess depression, anxiety and quality of life during the 12 months.

Patients randomized in group 2 will receive 1 to 3 MI. Patients randomized in group 3 will receive 1 to 3 MI and 6 CBT sessions by a psychotherapist.

Patients randomized in group 4 will receive 1 to 3 MI and at least 3 sessions oh hypnotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years.
* Smoking patient: daily tobacco consumption.
* Patient with cancer requiring surgical treatment (breast cancer, digestive cancer, gynecological).
* Patient wishing to quit smoking.
* Fagerström \> 3.
* Patient has valid health insurance
* Information and agreement of the patient to participate in the longitudinal cohort.
* Signing of specific informed consent for patients in groups 1 to 4 before any study-related intervention.
* Person able to speak, read and understand French.

Exclusion Criteria:

* Patient not receiving surgical treatment.
* Refusal to participate in the longitudinal cohort study.
* Pregnant or likely to be pregnant or nursing patient.
* Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian
* disability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.
Microcurrent Treatment for Chronic Debilitating Pain

To compare the efficacy of standard pain treatment and placebo (a microcurrent faux treatment) as opposed to standard pain treatment and microcurrent therapy in any primary care patients over a three month period.

This study is not intended to be definitive and should be considered an exploratory randomized trial to determine conditions for which microcurrent is more effective. Thus, extensive subgroup analyses will be performed so that definitive trials can be developed. This is a single-blind study where subjects will not know if they are receiving microcurrent treatment.

Eligibility Criteria:
\*\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\*\*

Inclusion Criteria:

* Male and female Active Duty members and DoD beneficiaries
* Age 18 years or older
* Chronic debilitating pain
* PROMIS-57 T score is 60 or above

Exclusion Criteria:

* Pregnant
* Implanted pacemaker
* Spinal cord stimulator
* Illicit drug use including marijuana use
* Epilepsy or a history of seizures
* Other implanted device (e.g., insulin pump, opioid pump, or defibrillator)
* Chronic debilitating pain referred or recruited as measured by PROMIS-57 T score is below 60
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.


Eligibility Criteria:
Inclusion Criteria:

* Type 2 diabetes
* Diet and lifestyle changes or metformin monotherapy for at least three months
* HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)
* Body Mass Index (BMI) less than or equal to 40 kg/m\^2

Exclusion Criteria:

* Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator)
* Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial
* Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening
* Current smoker or history of smoking within 6 months prior to screening
* Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease)
* Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator
* Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator
* Known autonomic neuropathy, as judged by the Investigator
* Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening
* Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg
Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia

Ventilator acquired pneumonia (VAP) are severe nosocomial infections. On the other side, bronchial fungi colonization is commonly observed in ICU; therefore, the investigators propose to study the role of bronchial fungi colonization on the occurrence of VAP taking into account the immune status of the patient and the antibiotic and antifungal treatments he has received.


Eligibility Criteria:
Inclusion Criteria:

* patient ventilated for at least 5 days

Exclusion Criteria:

* invasive infection Candida sp defined by : candidemia, isolation of Candida from a normally sterile site, candida pneumoniae.
Treatment of Erectile Dysfunction I

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).


Eligibility Criteria:
Inclusion Criteria:

* Male, at least 19 years of age
* Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
* Partner is not pregnant or lactating

Exclusion Criteria:

* History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
* Cardiac arrhythmias requiring antiarrhythmic treatment
* Symptomatic congestive heart failure
* Taking nitrate medication in any form
* Uncontrolled diabetes (HbA1c ≥ 13%)
* Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
* Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®